Skip to main content

Advertisement

SpringerLink
Log in

Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case–control study

  • Original Paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Accumulating evidence supports a role for obesity in the etiology of multiple myeloma (MM). The distinct possibility exists that obesity may be linked to MM through altered adipokine secretion and circulating levels, one of which, adiponectin, has a protective role in several malignancies, including leukemia. In this case–control study, we investigated the role of serum adiponectin, resistin, and leptin levels in the etiopathogenesis of MM and we explored their association with several established prognostic factors. Seventy three patients with incident, histologically confirmed MM and 73 controls matched on gender and age were studied between 2001 and 2007, and blood samples were collected. Serum adiponectin, leptin, resistin, as well as MM prognostic parameters were determined. Statistical analysis of the data was performed using univariate and multivariate analyses. Lower serum adiponectin and resistin levels were associated with higher risk of MM by bivariate analysis and after adjusting for age, gender, BMI, and serum levels of leptin (p < 0.0001). Adiponectin may have a protective role in MM, whereas leptin was not associated with risk for MM at a comparable level of significance and resistin levels may be decreased via a compensatory mechanism. Further studies are needed to confirm these associations and to explore the mechanisms underlying adiponectin’s role in MM and plasma cell dyscrasias.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Foerster J, Paraskevas F (1998) Multiple myeloma. In: Lee GR, Foerster J, Luken J, Paraskevas F, Greer JP, Rodgers GM, Wintrobe MM (eds) Wintrobe’s clinical hematology, vol 2. Lippincott Williams & Wilkins, Baltimore, pp 2631–2655

    Google Scholar 

  2. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860–1873. doi:10.1056/NEJMra041875

    Article  PubMed  CAS  Google Scholar 

  3. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  4. Lewis DR, Pottern LM, Brown LM, Silverman DT, Hayes RB, Schoenberg JB, Greenberg RS, Swanson GM, Schwartz AG, Liff JM (1994) Multiple myeloma among blacks and whites in the United States: the role of chronic antigenic stimulation. Cancer Causes Control 5:529–539. doi:10.1007/BF01831381

    Article  PubMed  CAS  Google Scholar 

  5. Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, Trichopoulos D (2007) Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 120:40–61. doi:10.1002/ijc.22718

    Article  PubMed  CAS  Google Scholar 

  6. Morgan GJ, Davies FE, Linet M (2002) Myeloma aetiology and epidemiology. Biomed Pharmacother 56:223–234. doi:10.1016/S0753-3322(02)00194-4

    Article  PubMed  CAS  Google Scholar 

  7. Bourguet CC, Logue EE (1993) Antigenic stimulation and multiple myeloma. A prospective study. Cancer 72:2148–2154. doi :10.1002/1097-0142(19931001)72:7<2148::AID-CNCR2820720714>3.0.CO;2-Q

    Article  PubMed  CAS  Google Scholar 

  8. Blair CK, Cerhan JR, Folsom AR, Ross JA (2005) Anthropometric characteristics and risk of multiple myeloma. Epidemiology 16:691–694. doi:10.1097/01.ede.0000172135.61188.2d

    Article  PubMed  Google Scholar 

  9. Birmann BM, Giovanucci E, Rosner B, Andesrson KC, Colditz GA (2007) Body mass index, physical activity and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 16:1474–1478. doi:10.1158/1055-9965.EPI-07-0143

    Article  PubMed  Google Scholar 

  10. Chiu BC, Gapstur SM, Greenland P, Wang R, Dyer A (2006) Body mass index, abnormal glucose metabolism and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev 15:2348–2354. doi:10.1158/1055-9965.EPI-06-0007

    Article  PubMed  CAS  Google Scholar 

  11. Larsson SC, Wolk A (2007) Body mass index and risk of multiple myeloma: a meta-analysis. Int J Cancer 121:2512–2516. doi:10.1002/ijc.22968

    Article  PubMed  CAS  Google Scholar 

  12. Chan JL, Moschos SJ, Bullen J, Heist K, Li X, Kim YB, Kahn BB, Mantzoros CS (2005) Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-alpha receptor levels in humans with relative leptin deficiency. J Clin Endocrinol Metab 90:1625–1631. doi:10.1210/jc.2004-1823

    Article  PubMed  CAS  Google Scholar 

  13. Matarese G, Moschos S, Mantzoros CS (2005) Leptin in immunology. J Immunol 174:3137–3142

    PubMed  CAS  Google Scholar 

  14. Brennan AM, Mantzoros CS (2006) Drug Insight: the role of leptin in human physiology and pathophysiology-emerging clinical applications. Nat Clin Pract Endocrinol Metab 2:318–327. doi:10.1038/ncpendmet0196

    Article  PubMed  CAS  Google Scholar 

  15. Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556. doi:10.1210/jc.2004-0395

    Article  PubMed  CAS  Google Scholar 

  16. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102–1107. doi:10.1210/jc.2003-031804

    Article  PubMed  CAS  Google Scholar 

  17. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C (2004) Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89:1160–1163. doi:10.1210/jc.2003-031716

    Article  PubMed  CAS  Google Scholar 

  18. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S (2005) Prostate cancer and adiponectin. Urology 65:1168–1172. doi:10.1016/j.urology.2004.12.053

    Article  PubMed  Google Scholar 

  19. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H (2005) Plasma adiponectin and gastric cancer. Clin Cancer Res 11:466–472. doi:10.1158/1078-0432.CCR-04-1453

    Article  PubMed  CAS  Google Scholar 

  20. Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS (2007) Low adiponectin levels are associated with renal cell carcinoma: a case–control study. Int J Cancer 120:1573–1578. doi:10.1002/ijc.22526

    Article  PubMed  CAS  Google Scholar 

  21. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97:1688–1694

    Article  PubMed  CAS  Google Scholar 

  22. Mantzoros CS, Trakatelli M, Gogas H, Dessypris N, Stratigos A, Chrousos GP, Petridou ET (2007) Circulating adiponectin levels in relation to melanoma: a case–control study. Eur J Cancer 43:1430–1436. doi:10.1016/j.ejca.2007.03.026

    Article  PubMed  CAS  Google Scholar 

  23. Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK, Trichopoulos D (2006) Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer 94:156–160. doi:10.1038/sj.bjc.6602896

    Article  PubMed  CAS  Google Scholar 

  24. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88:4848–4856. doi:10.1210/jc.2003-030519

    Article  PubMed  CAS  Google Scholar 

  25. Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O (2006) Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 28:241–244

    PubMed  CAS  Google Scholar 

  26. Alexandrakis MG, Passam FH, Sfiridaki A, Pappa CA, Moschandrea JA, Kandidakis E, Tsirakis G, Kyriakou DS (2004) Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. Int J Biol Markers 19:52–57

    PubMed  CAS  Google Scholar 

  27. Durie BGM (1986) Staging and kinetics of multiple myeloma. Semin Oncol 13:300–309

    PubMed  CAS  Google Scholar 

  28. Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842–854. doi :10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U

    Article  PubMed  CAS  Google Scholar 

  29. SAS/STAT User’s Guide (1989) NC, Cary. Ref Type: Computer Program

  30. Lauta VM (2003) A review of the cytokine network in multiple myeloma: diagnostic, prognostic and therapeutic implications. Cancer 97:2440–2452. doi:10.1002/cncr.11072

    Article  PubMed  CAS  Google Scholar 

  31. Ajuwon KM, Spurlock ME (2005) Adiponectin inhibits LPS-induced NF-kB activation and IL-6 production and increases PPARγ2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 288:1220–1225. doi:10.1152/ajpregu.00397.2004

    Google Scholar 

  32. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME (2004) Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 316:924–929. doi:10.1016/j.bbrc.2004.02.130

    Article  PubMed  CAS  Google Scholar 

  33. Nakao T, Hino M, Yamane T, Nishizawa Y, Morii H, Tatsumi N (1998) Expression of the leptin receptor in human leukaemic blast cells. Br J Haematol 102:740–745. doi:10.1046/j.1365-2141.1998.00843.x

    Article  PubMed  CAS  Google Scholar 

  34. Chan JL, Matarese G, Shetty GK, Raciti P, Kelesidis I, Aufiero D, De Rosa V, Perna F, Fontana S, Mantzoros CS (2006) Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc Natl Acad Sci USA 103:8481–8486. doi:10.1073/pnas.0505429103

    Article  PubMed  CAS  Google Scholar 

  35. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312. doi:10.1038/35053000

    Article  PubMed  CAS  Google Scholar 

  36. Rajala MW, Obici S, Scherer PE, Rossetti L (2003) Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111:225–230

    PubMed  CAS  Google Scholar 

  37. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R (2004) Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 314:415–419. doi:10.1016/j.bbrc.2003.12.104

    Article  PubMed  CAS  Google Scholar 

  38. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O’Rahilly S (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50:2199–2202. doi:10.2337/diabetes.50.10.2199

    Article  PubMed  CAS  Google Scholar 

  39. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111:932–939. doi:10.1161/01.CIR.0000155620.10387.43

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was supported by a discretionary grant from BIDMC.

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry, Medical School, University of Athens, “Attikon”, General University Hospital, 1 Rimini Street, Chaidari, 10024, Athens, Greece

    Maria Dalamaga, Anna Panagiotou & Cleanthi Dimas

  2. Department of Laboratory Hematology, NIMTS General Hospital, 12 Monis Petraki, and Vas.Sofias Avenue, 11521, Athens, Greece

    Maria Dalamaga & Antigoni Lekka

  3. Department of Internal Medicine-Hematology Section, NIMTS General Hospital, 12 Monis Petraki and Vas.Sofias Avenue, 11521, Athens, Greece

    Konstantinos Karmaniolas

  4. Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, ST816, Boston, MA, 02215, USA

    Alex Hsi, John Chamberland & Christos S. Mantzoros

Authors
  1. Maria Dalamaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Konstantinos Karmaniolas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Panagiotou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alex Hsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John Chamberland
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cleanthi Dimas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antigoni Lekka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christos S. Mantzoros
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christos S. Mantzoros.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dalamaga, M., Karmaniolas, K., Panagiotou, A. et al. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case–control study. Cancer Causes Control 20, 193–199 (2009). https://doi.org/10.1007/s10552-008-9233-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-008-9233-7

Keywords

Search

Navigation